How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,757 results for

Mycosis Fungoides

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Donor-derived mycosis fungoides following reduced intensity haematopoietic stem cell transplantation from a matched unrelated donor (PubMed)

Donor-derived mycosis fungoides following reduced intensity haematopoietic stem cell transplantation from a matched unrelated donor A 46-year-old woman with a history of dasatinib-resistant chronic myeloid leukaemia, clonal evolution and monosomy 7 underwent reduced intensity conditioned in vivo T-cell-depleted allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor. Following the transplantation, she developed recurrent cutaneous graft versus host disease (...) (GvHD), which required treatment with systemic immunosuppression and electrocorporeal photophoresis. Concurrently, she developed a lichenoid rash with granulomatous features suggestive of cutaneous sarcoidosis. Additional treatment with hydroxychloroquine was initially successful, but 2 months later, she developed erythroderma with palpable lymphadenopathy. Repeated histological analysis established a diagnosis of folliculotropic mycosis fungoides stage IVA2, and the malignant clone was confirmed

Full Text available with Trip Pro

2017 BMJ case reports

162. Immunohistopathological Study of c-FLIP Protein in Mycosis Fungoides (PubMed)

Immunohistopathological Study of c-FLIP Protein in Mycosis Fungoides Background: Mycosis fungoides (MF) is the commonest variant of primary cutaneous T cell lymphoma with several clinicopathologic variants. Defective apoptotic mechanism may be important in the pathogenesis and progression of MF. c-FLIP protein is an important anti-apoptotic marker and chemotherapeutic resistant factor. This study aimed to evaluate the c-FLIP expression in MF and its role in the pathogenesis of MF. Methods

Full Text available with Trip Pro

2017 Asian Pacific journal of cancer prevention : APJCP

163. Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome vs. HTLV-1+ leukemic cell lines (PubMed)

Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome vs. HTLV-1+ leukemic cell lines HTLV-1 is estimated to affect ~20 million people worldwide and in ~5% of carriers it produces Adult T-Cell Leukemia/Lymphoma (ATLL), which can often masquerade and present with classic erythematous pruritic patches and plaques that are typically seen in Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most recognized variants of Cutaneous T-Cell Lymphomas

Full Text available with Trip Pro

2017 Oncotarget

164. Mycosis fungoides presenting as symmetric concentric patches mimicking figurate erythema (PubMed)

Mycosis fungoides presenting as symmetric concentric patches mimicking figurate erythema 28702497 2019 02 26 2352-5126 3 4 2017 Jul JAAD case reports JAAD Case Rep Mycosis fungoides presenting as symmetric concentric patches mimicking figurate erythema. 288-290 10.1016/j.jdcr.2017.03.013 Notay Manisha M Department of Dermatology, University of California Davis, Sacramento, California. Petukhova Tatyana A TA Department of Dermatology, University of California Davis, Sacramento, California. Kiuru (...) 101665210 2352-5126 EAC, erythema annulare centrifugum MF, mycosis fungoides Mycosis fungoides T-cell receptor gene rearrangement TCR, T-cell receptor biopsy cutaneous T-cell lymphoma figurate erythema polymerase chain reaction 2017 7 14 6 0 2017 7 14 6 0 2017 7 14 6 1 epublish 28702497 10.1016/j.jdcr.2017.03.013 S2352-5126(17)30076-0 PMC5484965 Br J Dermatol. 2009 Jan;160(1):119-26 18721189 Blood. 2005 May 15;105(10):3768-85 15692063 J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2 24438969

Full Text available with Trip Pro

2017 JAAD Case Reports

165. Hypopigmented Mycosis Fungoides versus Mycosis Fungoides with Concomitant Hypopigmented Lesions: Same Disease or Different Variants of Mycosis Fungoides? (PubMed)

Hypopigmented Mycosis Fungoides versus Mycosis Fungoides with Concomitant Hypopigmented Lesions: Same Disease or Different Variants of Mycosis Fungoides? Hypopigmented mycosis fungoides (HMF) is a rare subtype of mycosis fungoides (MF). We compared patients with exclusive hypopigmented lesions with a group of MF patients with concomitant different lesions.20 patients with HMF only and 14 patients with hypopigmented lesions concomitant with other types of lesions (mixed MF, MMF) were selected

2014 Dermatology

166. Phototherapy for early-stage mycosis fungoides

Phototherapy for early-stage mycosis fungoides Phototherapy for early-stage mycosis fungoides Phototherapy for early-stage mycosis fungoides Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Phototherapy for early-stage mycosis fungoides. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication Dates. 2012 Authors' conclusions Cutaneous T-cell lymphomas (...) (CTCL) are a heterogeneous group of non-Hodgkin's lymphomas characterized by their initial manifestation in the skin. Mycosis fungoides (MF), which evolves from scaly skin patches and plaques, is the most common form of CTCL affecting approximately 65% of cases. The incidence of MF in the United States has been estimated at 6 cases per 1 million individuals with a male predominance. MF is broadly divided into early- and advanced-stage disease and classified into four clinical stages (I-IV). Skin

2012 Health Technology Assessment (HTA) Database.

167. Concomitant Mycosis Fungoides and Vitiligo: How Mycosis Fungoides May Contribute to Melanocyte Destruction. (PubMed)

Concomitant Mycosis Fungoides and Vitiligo: How Mycosis Fungoides May Contribute to Melanocyte Destruction. Few reports have described vitiligo developing in patients with cutaneous T-cell lymphoma (CTCL).We sought to identify possible factors that might predispose patients with CTCL to vitiligo.Patient demographics, CTCL disease characteristics and treatments were analyzed in 25 patients with CTCL who developed vitiligo. Cox proportional hazards modeling was used to identify associations (...) of risk factors with the development of vitiligo.Younger age, later CTCL disease stage (stages IIB-IV) and presence of a CD8+CD4- mycosis fungoides phenotype were associated with the development of vitiligo. After adjusting for disease stage, increased risk of vitiligo was associated with methotrexate and CD4 antibody therapies (although the total number of patients with these was small), while decreased risk was associated with nitrogen mustard and PUVA therapies.No single feature was common to all

2015 Dermatology

168. Amlodipine-induced hypersensitivity reaction mimicking CD30+ mycosis fungoides (PubMed)

Amlodipine-induced hypersensitivity reaction mimicking CD30+ mycosis fungoides 27570814 2016 08 29 2019 02 26 2352-5126 2 4 2016 Jul JAAD case reports JAAD Case Rep Amlodipine-induced hypersensitivity reaction mimicking CD30(+) mycosis fungoides. 320-2 10.1016/j.jdcr.2016.06.013 Gochoco Ashley A Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, Pennsylvania. Jones Elizabeth E Department of Dermatology and Cutaneous Biology, Thomas Jefferson University (...) JAAD Case Rep 101665210 2352-5126 GVHD, graft-versus-host disease amlodipine cutaneous T-cell lymphoma drug reaction mycosis fungoides 2016 8 30 6 0 2016 8 30 6 0 2016 8 30 6 1 epublish 27570814 10.1016/j.jdcr.2016.06.013 S2352-5126(16)30063-7 PMC4992011 J Cutan Pathol. 2008 Apr;35(4):358-65 17976210 J Eur Acad Dermatol Venereol. 2008 Dec;22(12):1522-4 18452522 Eur J Dermatol. 2009 May-Jun;19(3):292-4 19336342 Clin Drug Investig. 2006;26(3):125-33 17163243 Arch Intern Med. 1989 Apr;149(4):829-32

Full Text available with Trip Pro

2016 JAAD Case Reports

169. Correlation between mycosis fungoides and pregnancy (PubMed)

Correlation between mycosis fungoides and pregnancy To evaluate the effect of pregnancy on the natural course of Mycosis fungoides (MF) and compare the obtained results with previous reports.The medical records of 140 patients with cutaneous T-cell lymphoma (CTCL) treated at the University Hospital of Isfahan (the academic referral center for CTCL) Isfahan, Iran. Between 2000 and 2013 were retrospectively reviewed to retrieve all cases of pregnancy during the course of MF disease. A total of 8 (...) pregnancies were recorded. The median age of patients at the time of diagnosis was 26.7 (range 21-30 years) and pregnancy 29.4 (range 27-31 years). Most of patients had early-stage MF (Ia and Ib). All patients experienced aggravation of disease during pregnancy or immediately postpartum. Mycosis fungoides did not cause any complications during pregnancy. Pregnancy appears to have a negative impact on the course of MF, probably due to immune system deteriorations during the pregnancy. Further studies

Full Text available with Trip Pro

2016 Saudi medical journal

170. Surgical Excision of Mycosis Fungoides Using Thumb-Sparing Reconstruction (PubMed)

Surgical Excision of Mycosis Fungoides Using Thumb-Sparing Reconstruction Background: The differential for soft tissue tumors of the hand and upper limb is broad. Hematologic malignancy remains quite low on the differential for soft tissue tumors involving the hand, and there is little in the literature describing surgical management of such cutaneous manifestations. When the tumor is large or involves the thumb, careful consideration of reconstructive options is required. Methods: We present (...) a rare case of an aggressively enlarging mycosis fungoides, a cutaneous T-cell lymphoma tumor, involving the thumb. This tumor had a history of multiple failed treatment attempts, including radiation and chemotherapy. Results: Our surgical plan was a reverse radial forearm osteocutaneous flap. Conclusion: A reverse radial osteocutaneous forearm flap was successfully used to avoid thumb amputation and preserve thumb function.

Full Text available with Trip Pro

2016 Hand (New York, N.Y.)

171. IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression (PubMed)

IL-32 induces indoleamine 2,3-dioxygenase+CD1c+ dendritic cells and indoleamine 2,3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression Mycosis fungoides (MF) progresses from patch to tumor stage by expansion of malignant T-cells that fail to be controlled by protective immune mechanisms. In this study, we focused on IL-32, a cytokine, highly expressed in MF lesions. Depending on the other cytokines (IL-4, GM-CSF) present during in vitro culture of healthy volunteers

Full Text available with Trip Pro

2016 Oncoimmunology

172. Pityriasis Lichenoides-like Mycosis Fungoides: Clinical and Histologic Features and Response to Phototherapy (PubMed)

Pityriasis Lichenoides-like Mycosis Fungoides: Clinical and Histologic Features and Response to Phototherapy Pityriasis lichenoides (PL)-like skin lesions rarely appear as a specific manifestation of mycosis fungoides (MF).We investigated the clinicopathological features, immunophenotypes, and treatments of PL-like MF.This study included 15 patients with PL-like lesions selected from a population of 316 patients diagnosed with MF at one institution.The patients were between 4 and 59 years

Full Text available with Trip Pro

2016 Annals of dermatology

173. ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. ID Of Prognostic Factors (...) In Mycosis Fungoides/Sezary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT02848274 Recruitment Status : Recruiting First Posted : July 28, 2016 Last Update Posted : February 11, 2019 See Sponsor: Stanford University

2016 Clinical Trials

174. Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)

Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (RESMAIN) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2016 Clinical Trials

175. Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2016 Clinical Trials

176. TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. TSEB (...) and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02822586 Recruitment Status : Active, not recruiting First Posted : July 4, 2016 Last Update Posted : February 25, 2019 Sponsor: Virginia Commonwealth University Collaborator: Seattle Genetics

2016 Clinical Trials

177. Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details

2016 Clinical Trials

178. Biopsy correlation of surface area vs single axis measurements on CT scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sezary syndrome. (PubMed)

Biopsy correlation of surface area vs single axis measurements on CT scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sezary syndrome. 28012157 2018 08 13 2018 08 13 1365-2133 177 3 2017 09 The British journal of dermatology Br. J. Dermatol. Biopsy correlation of surface area vs. single-axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and Sézary syndrome. 877-878 10.1111/bjd.15266 Haththotuwa R R Department (...) . Shah F F Department of Dermatology, University Hospitals Birmingham, Birmingham, U.K. Chaganti S S Department of Haematology, University Hospitals Birmingham, Birmingham, U.K. Scarisbrick J J Department of Dermatology, University Hospitals Birmingham, Birmingham, U.K. eng Letter 2017 07 31 England Br J Dermatol 0004041 0007-0963 IM Biopsy Dermatitis, Exfoliative pathology Humans Lymph Nodes pathology Lymphatic Metastasis Mycosis Fungoides pathology Retrospective Studies Sezary Syndrome pathology

2016 British Journal of Dermatology

179. Mycosis fungoides staged by 18F-flurodeoxyglucose positron emission tomography/computed tomography: Case report and review of literature. (PubMed)

Mycosis fungoides staged by 18F-flurodeoxyglucose positron emission tomography/computed tomography: Case report and review of literature. Mycosis fungoides is a kind of malignant lymphoma arising from T cells, but primarily occurs in skin, and it is the most common type of cutaneous lymphoma. Mycosis fungoides (MF) is a rare non-Hodgkin lymphoma but the most common type of primary cutaneous T-cell lymphomas. Because of unknown etiology and mechanism, and lack of typical clinical

Full Text available with Trip Pro

2016 Medicine

180. The biomarker landscape in mycosis fungoides and sézary syndrome. (PubMed)

The biomarker landscape in mycosis fungoides and sézary syndrome. The practice of pre-emptive individualized medicine is predicated on the discovery, development and application of biomarkers in specific clinical settings. Mycosis fungoides and Sézary syndrome are the two most common type of cutaneous T-cell lymphoma, yet diagnosis, prognosis and disease monitoring remain a challenge. In this review, we discuss the current state of biomarker discovery in mycosis fungoides and Sézary syndrome

Full Text available with Trip Pro

2016 Experimental Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>